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full recovery. They subsequently excluded
the same groups of patients from the ideal
scenario in which all patients were admitted
within the time window for thrombolysis.
Had thrombolysis actually been given, the
outcomes for these patients would have
been unknown at the time of administration.
These patients should therefore have been
included in the analysis.
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Another trial is needed
Editor—The paper by Jørgensen et al
provides a small counterbalance to the
enormous propaganda behind an expen-
sive, minimally tested, and potentially harm-
ful intervention.1 The real ratio of benefit to
risk of thrombolytics for stroke may even be
far worse than Jørgensen et al calculate, for
the following reasons.
Firstly, even fewer stroke patients in com-
munity practice would qualify for treatment
with alteplase if a strict three hour cut-off
point for completion of all diagnostic
activities and initiation of the drug were used.
Secondly, inclusion of even a few of
those patients with seizure, tumour, infec-
tion, etc, whose condition mimics stroke and
who constitute perhaps 15-25% of patients
diagnosed as having “stroke” in community
practice but were rare in the expert based
National Institute of Neurological Disorders
and Stroke (NINDS) trial,2 could easily over-
whelm any benefits of alteplase, since such
patients cannot possibly benefit from treat-
ment but can certainly be harmed.
Thirdly, treatment of even a few patients
with subtle haemorrhage, undetected
because the computed tomography scan was
not read by a neuroradiologist, would have
the same effect—and there is good evidence
that very few general radiologists, neurolo-
gists, or emergency physicians are able to
identify most or all such haemorrhages.
Fourthly, treatment outside the special-
ised environments used in NINDS, and with-
out the experts participating in such studies,
could lead to far more harm when a drug that
produces such a high rate of intracranial
haemorrhage under ideal conditions is used.
Fifthly, of seven trials of lytics in stroke to
date, only the fairly small NINDS trial has
had positive results—the results of the six
that have been either neutral or negative
(including several with dramatically
increased mortality in patients treated with
thrombolytics) are typically ignored.
“Another trial is needed” is a generous
summary of the available evidence. Given the
extremely limited evidence of efficacy, the
marginal nature of that efficacy (under the
best of circumstances), and the strong
likelihood that such efficacy will not translate
into effectiveness in community practice—as
well as the real potential for harm—approval
of this drug in the United Kingdom, for the
treatment of stroke should be withheld unless
and until far more definitive evidence (for
effectiveness as well as for efficacy) is
forthcoming.
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Author’s reply
Editor—Our simulation model of intra-
venous thrombolysis (using alteplase) in
patients with acute stroke model had two
purposes: firstly, to estimate the target popu-
lation for intravenous thrombolysis in an
unselected population of patients with acute
stroke; and, secondly, to estimate the
number of patients who would actually ben-
efit from this treatment—provided that the
results of the only trial with positive reults so
far, the National Institute of Neurological
Disorders and Stroke (NINDS) trial,1 can be
reproduced.
In the study we included the 1197
patients from the Copenhagen stroke study, a
community based study in which all patients
with acute stroke from a well defined
catchment area of Copenhagen had all their
acute treatment and rehabilitation in one
large stroke unit regardless of their age, the
severity of the stroke, and their comorbidity
prior to stroke. In the first part of our analysis
we estimated the target population for
alteplase treatment using the inclusion crite-
ria from the NINDS trial. We included
patients who eventually died or who recov-
ered fully. A disappointing rate of only 4% of
the patients fulfilled the inclusion criteria.
To estimate the number of patients who
would have benefited from intravenous
thrombolysis we excluded the patients who
either recovered fully and had no functional
disability after completed rehabilitation or
who died during hospital stay. Berwaerts et al
argue that these patients should have been
included as the outcomes for them would
have been unknown at the time of drug
administration. We believe, however, that it
was justified to exclude them from the analy-
sis of the number of patients who would actu-
ally benefit from alteplase treatment. None of
these patients would have benefited from
treatment because they either had a complete
recovery without thrombolysis or they died.
As the NINDS trial shows, alteplase treatment
has no effect on overall mortality.
The results of our study in combination
with the arguments offered by Hoffman
should raise serious questions about the
approval of intravenous thrombolysis in
patients with acute stroke. The possible, but
not proved, marginal benefit of intravenous
thrombolysis in a very small number of
patients (1 out of 160 patients in our simula-
tion model) should be considered in
contrast to the marked benefit of treatment
and rehabilitation of unselected patients in
specialised stroke units,2–5 regardless of their
age, sex, severity of stroke, and comorbidity.
Economic resources are limited and should
be used where they benefit most patients in
the most effective way—in this case by
providing early, intensive rehabilitation to all
patients in dedicated stroke units.
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Intention to treat analysis is
related to methodological
quality
Editor—In their survey of all randomised
controlled trials published in 1997 in four
major medical journals, Hollis and Campbell
found that only 48% of the reports explicitly
mentioned intention to treat analysis.1 In a
considerable proportion it was insufficiently
described and sometimes inadequately
applied. Their results are confirmed by our
assessment of all randomised controlled trials
published between 1993 and 1995 in the
same four journals.2 In addition to our assess-
ment of ethical issues, we calculated the
proportion of randomised controlled trials
reporting intention to treat analysis in
accordance with different descriptive and
methodological characteristics.
In our review of 608 randomised
controlled trials, we found that 290 of the
trials (47.7%) explicitly mentioned that they
applied the principle of intention to treat
analysis. The reporting of this issue
increased slightly between 1993 and 1995
(although the increase was not significant).
Trials with a greater number of participants
and those funded by the pharmaceutical
industry were more likely to report the
application of the intention to treat princi-
ple (table). In the multivariable logistic
regression analysis, when we controlled for
the general characteristics previously
described, we found that trials with survival
of patients as the principal outcome were
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more frequently reported to follow the
intention to treat principle. In addition,
those randomised controlled trials that gave
no information about sample size were less
likely to report the use of this principle
(table). Randomised controlled trials not
reporting the number of withdrawals or
losses to follow up and those not reporting
information about compliance with treat-
ment were also less likely to report the
intention to treat principle, although these
results were not significant.
Our data support the relation between a
higher methodological quality of the trials
and the reporting of the intention to treat
analysis. Our results reinforce the conclu-
sions of Hollis and Campbell that the appli-
cation of this principle still needs to
improve because it seems that there has
been no improvement between 1993 and
1997.1 A joint effort of editors and research-
ers is needed to meet the CONSORT
guidelines3 and the authors’ recommenda-
tions favouring intention to treat analysis.1
A better quality of reporting will help read-
ers to assess the design, conduct, and analy-
sis of randomised controlled trials more
critically.
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Using anticoagulation or
aspirin to prevent stroke
Research was methodologically flawed
Editor—The paper by Hellemons et al is
not justified in concluding that aspirin is the
prophylactic choice in primary care for
atrial fibrillation, if there is no clear
indication for full anticoagulation.1
The study is methodologically flawed. As
clinicians, we ask ourselves: “Which patient
in atrial fibrillation should be given anti-
coagulants?” This is a statistical question
about the risks and benefits of aspirin or
warfarin for that individual patient.
In the power calculation Hellemons et al
asked whether low anticoagulation (inter-
national normalised ratio 1.1-1.6) or aspirin
should be used—but this is the wrong
question. The choice should have been
between aspirin and standard anticoagula-
tion (INR 2.5-3.5). The increased incidence
of major intracranial bleeding in the aspirin
group compared with the anticoagulated
groups (0.75% per patient year v 0.35%)
calls into question the sagacity of using one
tailed statistical tests.
As the study was underpowered, the
question of whether standard anticoagula-
tion or aspirin was better in preventing
major cerebral infarction cannot be
answered. Although there is a trend towards
full anticoagulation (hazard ratio 0.67), the
95% confidence intervals are so wide (0.11
to 4.1) that the result is meaningless.
The arbitrary exclusion from standard
anticoagulation of all people who were 78
years or older also undermines the study, for
although it may have reduced the complica-
tion rate from anticoagulation, it will have
also reduced the potential benefit.
This paper highlights the problems in
reporting “negative” or “no difference” stud-
ies. It has failed to show “no difference”
between standard anticoagulation and aspi-
rin prophylaxis in atrial fibrillation, as
clinically important differences could well
exist within the confidence limits. The study
adds little to previous work that does
demonstrate benefit from anticoagulation2
and may be misinterpreted as an excuse for
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All sample 608 290 (47.7)
Descriptive characteristics of the trials
Journal:
N Engl J Med 219 122 (55.7) 1 1
JAMA 81 37 (45.7) 1.50 (0.90 to 2.50) 1.64 (0.92 to 2.92)
BMJ 105 44 (41.9) 1.74 (1.09 to 2.79) 1.80 (0.96 to 3.39)
Lancet 203 87 (42.9) 1.68 (1.14 to 2.46) 1.54 (0.95 to 2.50)
Year of publication:
1995 211 108 (51.2) 1 1
1994 195 92 (47.2) 1.17 (0.79 to 1.73) 1.20 (0.78 to 1.86)




164 86 (52.4) 1 1
United Kingdom 127 61 (48.0) 1.19 (0.75 to 1.90) 0.90 (0.52 to 1.55)
United States 240 120 (50.0) 1.10 (0.74 to 1.64) 1.24 (0.75 to 2.07)
Other 77 23 (29.9) 2.59 (1.45 to 4.60) 2.59 (1.38 to 4.85)
Main specialty of authors:
Medical specialties 432 213 (49.3) 1 1
Surgery or
medical-surgical
106 45 (42.5) 1.32 (0.86 to 2.02) 1.23 (0.76 to 1.99)
Intensive or emergency
care
37 18 (48.6) 1.03 (0.52 to 2.01) 1.08 (0.51 to 2.29)
Public health 16 7 (43.8) 1.25 (0.46 to 3.42) 1.60 (0.54 to 4.74)
Other 17 7 (41.2) 1.39 (0.52 to 3.72) 1.29 (0.44 to 3.82)
Number of participating subjects:
>500 171 109 (63.7) 1 1
51 to 500 322 167 (51.9) 1.63 (1.11 to 2.39) 1.68 (1.12 to 2.53)
<50 115 14 (12.2) 12.66 (6.68 to 24.10) 12.43 (6.24 to 24.36)
Source of funding:
Pharmaceutical industry 206 129 (62.6) 1 1
Public agency 165 73 (44.2) 2.11 (1.39 to 3.20) 2.11 (1.34 to 3.34)
Other 126 52 (41.3) 2.38 (1.52 to 3.75) 2.01 (1.22 to 3.30)
Not reported 111 36 (32.4) 3.49 (2.14 to 5.68) 2.35 (1.34 to 4.10)
Methodological characteristics of the trials
Outcome:
Survival 142 104 (73.2) 1 1
Other 466 186 (39.9) 4.12 (2.72 to 6.24) 2.86 (1.77 to 4.60)
Sample size estimation:
Shown 281 167 (59.4) 1 1
Not shown 327 123 (37.6) 2.43 (1.75 to 3.37) 2.28 (1.55 to 3.37)
Compliance with treatment:
Stated 532 261 (49.1) 1 1
Not stated 76 29 (38.2) 1.56 (0.95 to 2.56) 1.71 (0.98 to 2.99)
Reporting follow up or withdrawals:
Reporting the number of
patients withdrawn or lost
to follow up
194 100 (51.5) 1 1
Not giving information
about number of patients
lost to follow up
414 190 (45.9) 1.25 (0.89 to 1.76) 1.45 (0.98 to 2.14)
A higher odds ratio means a higher probability of not reporting the use of the intention to treat principle.
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